Posted by Michael Wonder on 25 Sep 2023
Once weekly Altuviiio approved in Japan as a new class of factor VIII therapy for haemophilia A
25 September 2023 - Approval demonstrates commitment to delivering innovation and a paradigm shift in the haemophilia treatment landscape.
The Japanese Ministry of Health, Labor, and Welfare has granted marketing authorisation for Altuviiio [anti-haemophilic factor (recombinant), Fc-VWF-XTEN fusion protein], a first in class, high-sustained factor VIII replacement therapy.
